In HCC, β-catenin activation drives anti-PD-1 resistance in engineered mouse models and has been linked to non-response in early clinical series, establishing CTNNB1-mutant HCC as a biomarker-defined immune-excluded class [9,10]. Here, CTNNB1 is linked to hepatocellular carcinoma.